Verseon Corporation Additional Listing & Total Voting Rights (6009G)

TIDMVSN

RNS Number : 6009G

Verseon Corporation

05 March 2018

March 5, 2018

Verseon Corporation

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 14,143 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to the regular vesting of restricted stock units and warrant exercise (the "Issuance").

The 14,143 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on March 8, 2018.

Total Voting Rights

Following the Issuance, the issued share capital of the Company will consist of 151,570,945 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,528,028. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact

 
 Verseon Corporation                  www.verseon.com 
                                      +1 (510) 225 
 Sebastian Wykeham / Tina Schlafly     9000 
 
 Cenkos Securities (NOMAD and 
  Joint Broker) 
                                       +44 (0) 20 
 Neil McDonald / Beth McKiernan         7397 8900 
 
 Cantor Fitzgerald Europe (Joint 
  Broker) 
 Marc Milmo / Phil Davies /           +44 (0) 20 
  Callum Butterfield                   7894 7000 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd 
  (PR Advisers) 
 Henry Harrison-Topham / Jamie    +44 (0) 20 
  Hooper                           7466 5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 
 Simon Vane Percy         821 890 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKDAESDPEFF

(END) Dow Jones Newswires

March 05, 2018 02:00 ET (07:00 GMT)